Drug-induced liver injury (DILI) is a significant concern in clinical practice, arising from medications, herbs, and dietary supplements. It can ...

It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...

In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology published a consensus on primary ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...

Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...

As part of the 'Ren Xin' initiative, a guidebook titled 'Handbook for TCM Practitioners and Traders in Malaysia' was published in November 2023 to raise awareness about the negative impact of using ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...

That leaves patients with limited second-line options for treatment if they fail to respond to or cannot tolerate ursodeoxycholic acid (UDCA), the standard first-line therapy, according to the ...

Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – ...